Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design

被引：0
|
作者：
Montalban, X. [11 ]
Linker, R. [1 ]
Centonze, D. [2 ,3 ]
Turner, B. [4 ]
Sanchez-de la Rosa, R. [5 ]
Nillos, L. [6 ]
Ettle, B. [7 ]
Raponi, E. [8 ]
Thouvenot, E. [9 ,10 ]
机构：
[1] Univ Regensburg, Univ Str, Regensburg, Germany
[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy
[3] IRCCS Neuromed, Neurol Unit, Rome, Italy
[4] Royal London Hosp, Dept Neurol, London, England
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Corp Malaysia Sdn Bhd, Petaling Jaya, Selangor, Malaysia
[7] Novartis Pharma GmbH, Nurnberg, Germany
[8] Novartis Pharma SAS, Rueil Malmaison, France
[9] Univ Montpellier, CNRS, Inst Genom Fonct, INSERM, Montpellier, France
[10] Nimes Univ Hosp, Dept Neurol, Nimes, France
[11] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-224
引用
收藏
页码：357 / 358
页数：2
相关论文
共 50 条
  • [21] CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
    Wang, J.
    Wang, Z.
    Wu, L.
    Li, B.
    Cheng, Y.
    Li, X.
    Wang, X.
    Han, L.
    Wu, X.
    Fan, Y.
    Yu, Y.
    Lv, D.
    Shi, J.
    Huang, J.
    Zhou, S.
    Han, B.
    Sun, G.
    Guo, Q.
    Ji, Y.
    Zhu, X.
    Hu, S.
    Zhang, W.
    Wang, Q.
    Jia, Y.
    Wang, Z.
    Song, Y.
    Wu, J.
    Shi, M.
    Li, X.
    Han, Z.
    Liu, Y.
    Yu, Z.
    Liu, A.
    Wang, X.
    Zhou, C.
    Zhong, D.
    Miao, L.
    Zhang, Z.
    Zhao, H.
    Yang, J.
    Wang, D.
    Wang, Y.
    Li, Q.
    Zhang, X.
    Ji, M.
    Yang, Z.
    Cui, J.
    Gao, B.
    Wang, B.
    Liu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S927 - S928
  • [22] Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Loong, Herbert
    Goto, Koichi
    Solomon, Benjamin
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Cheng, Ying
    Ardizzoni, Andrea
    Mak, Milena
    Santini, Fernando
    Elamin, Yasir
    Drilon, Alexander
    Wolf, Juergen
    Han, Baohui
    Han, Hongmei
    Uh, Minji
    Puri, Tarun
    Soldatenkova, Viktoriya
    Zhou, Caicun
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 246 - 246
  • [23] EFFICACY AND TOLERABILITY OF BEVACIZUMAB (B) AND ERLOTINIB (E) AS FIRST-LINE THERAPY IN ASIAN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A PHASE II TRIAL
    Hsu, C.
    Kang, Y.
    Yang, T. S.
    Su, W.
    Shun, C.
    Sandoval-Tan, J.
    Chiou, T.
    Jin, K.
    Hsu, C.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 237 - 237
  • [24] Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
    Michelino De Laurentiis
    Simona Borstnar
    Mario Campone
    Ellen Warner
    Javier Salvador Bofill
    William Jacot
    Susan Dent
    Miguel Martin
    Alistair Ring
    Paul Cottu
    Janice Lu
    Eva Ciruelos
    Hamdy A. Azim
    Sanjoy Chatterjee
    Katie Zhou
    Jiwen Wu
    Lakshmi Menon-Singh
    Claudio Zamagni
    Breast Cancer Research and Treatment, 2022, 191 : 223 - 224
  • [25] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
    De Castro, Gilberto, Jr.
    Tan, Daniel Shao-Weng
    Crino, Lucio
    Wu, Yi Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximilian
    Cortot, Alexis
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario Garcia
    Branle, Fabrice
    Sen, Paramita
    Mcculloch, Tracey
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S7 - S7
  • [26] Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina D.
    Fowler, Nathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S277 - S278
  • [27] Effectiveness of Axicabtagene Ciloleucel Versus Conventional Treatments as First-line Therapy in Patients With High-risk Large B-cell Lymphoma: a Retrospective External Comparator Study
    Kim, Ju Hwan
    Bea, Sungho
    Choi, Yeeun
    Yoon, Sang Eun
    Kim, Won Seog
    Kim, Seok Jin
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 532
  • [28] Rationale and Design of a Phase 3b Study of the Long-Term Tolerability and Safety of HyQvia in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): ADVANCE-CIDP 3
    Hasan, Shabbir
    Duff, Kimberly
    Wisseh, Steve
    Youssef, Ashraf
    Chavan, Shailesh
    NEUROLOGY, 2020, 94 (15)
  • [29] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    LANCET, 2018, 391 (10126): : 1163 - 1173
12345